Leap Therapeutics (LPTX) Misses Q2 EPS by 40c

Leap Therapeutics (NASDAQ: LPTX) reported Q2 EPS of ($0.40), $0.40 worse than the analyst estimate of $0.00.

For earnings history and earnings-related data on Leap Therapeutics (LPTX) click here.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Sigma Lithium resumes full operations after signing TAC agreement